Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison

202248 citationsReviewdiamond Open Access

Authors

Findings from both ITCs (NMA and STC) support the use of tezepelumab in a broad patient population of severe uncontrolled asthma of any phenotype.

Good health and well-being

Published in: Journal of Medical Economics

Volume 25, Issue 1, pp. 679-690

Field-Weighted Citation Impact: 5.43